1 / 11

Dasatinib's Pharmacodynamic Biomarker for Prostate Cancer

Evaluate 18F-Fluoride PET as a pharmacodynamic biomarker for Dasatinib, a Src kinase inhibitor, in men with castration-resistant prostate cancer and bone metastases.

hsheila
Download Presentation

Dasatinib's Pharmacodynamic Biomarker for Prostate Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ACRIN 6687A Phase 2, Multicenter Evaluation of 18F-Fluoride PET as a Pharmacodynamic Biomarker for Dasatinib, a Src Kinase Inhibitor, in Men With Castration-Resistant Prostate Cancer and Bone Metastases Principal Investigators: Evan Y. Yu, MD and David A. Mankoff, MD, PhD

  2. Background ACRIN 6687 is a companion imaging protocol to accompany the therapeutic protocol “Genomic Guided Therapy with Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer.” (Dr. Phillip Febbo) supported through the Department of Defense and Bristol-Meyers Squibb Eligible patients currently enrolled in Dr. Febbo’s therapeutic trial and receiving dasatinib undergo 18F-fluoride PET imaging. This includes patients genetically indicated to have tumors with SRC microarray signatures who initial dasatinib-alone treatment, as well as those patients with initial AR microarray signatures who may crossover at the time of progression to have dasatinib added to nilutamide.

  3. AR Transcriptional Signature R1881 Gene expression “Signature” to detect AR activity Febbo et al, Urology (2005) Probability of AR Activity Metagene Score Mendiratta et al, JCO (2009)

  4. AR Transcriptional Signature Metastatic CRPC Neoadjuvant No Treatment Castration Resistant No Treatment After Castration AR activity correponded to tissue DHT levels Data from Holzbelerlein et al. Am J Path (2004) and Stanbrough et al Cancer Res (2007).

  5. Study Schema 18F-Fluoride PET 18F-Fluoride PET PCCTC and ACRIN Collaboration Progress ion Progress ion AR Activity Dasatinib 100 mg PO QD Nilutamide 150 mg PO QD • Metastatic, Castration Resistant Prostate Cancer • Disease Amenable to Biopsy • Castrate Testosterone Levels Biopsy > 0.50 < 0.50 Dasatinib 100 mg PO QD Nilutamide 150 mg PO QD 18F-Fluoride PET 18F-Fluoride PET

  6. Goals • Potential Insight Gained From the Trial: • 18F-fluoride PET evaluation of an agent, such as dasatinib, that is expected to affect both normal bone and bone metastases • Gain pharmacodynamic information with 18F-fluoride PET on the effects of dasatinib both on normal bone and bone metastases • Determine whether 18F-fluoride PET has prognostic and response biomarker potential for patients with bone metastatic prostate cancer

  7. Primary Endpoint Determine if changes in regional fluoride incorporation, measured by 18F-fluoride PET (SUV and Ki), occur in both castration-resistant prostate cancer bone metastases and normal bone as a response to treatment with dasatinib Secondary Endpoint: Determine if changes in 18F-fluoride transport (K1), an indicator of blood flow, and therefore, an indirect marker of angiogenesis, occur in both castration-resistant prostate cancer bone metastases and normal bone as a response to treatment with dasatinib Endpoints

  8. ACRIN 6687 Current Status • Accrual to Treatment Trial • Current Accrual: 54 (N= 60) • 6687 Imaging Protocol • Current Accrual: 12 (N=24) • A total of four (4) centers are approved to participate (UW, Duke, DFCI, OHSU) • Most recent site approval 9/24/10 • One site was unable to bring up the trial due to late timing of protocol approval • Potential to accrue at least two (2) of the accrued 54 as they may cross over to add on Dasatanib to ongoing Nilutamide • One (1) patient out of the 12 did not receive both PET images • Challenge: to reach 24 patient accrual goal – current discussions to expand therapeutic study by 10 patients

  9. Challenges Setting up IND tracer availability Companion Imaging on a subset of patients Delays to Site Readiness IRB approval for both the treatment and Imaging Trial slow Two (2) centers had IRB approval of the treatment trial before the imaging trial and both accrued to treatment trial rapidly Radiology Interest Barriers to Accrual Inclusion/Exclusion to original Febbo trial (protocol was amended) Unable to accrue beginning patients as treatment trial was opened prior to imaging trial Prostate cancer patients are elderly and many have painful bone metastases - reluctance to lay in scanner for extended time Challenges

  10. Completion of Accrual – Target by end of 2010 although treatment study may expand Complete PET Imaging and Data Collection for 6687 Patients Finalize Data Sharing with the Febbo Trial Continue Kinetic Analysis of PET Images Central Review of PET and Bone Scan Images Plans For Next Year - 2011

  11. Thank You

More Related